Competition & Peer Data API & CSV Delivery Connect to AI Assistant via MCP

Global Cord Blood's Competitiveness

A competitive positioning analysis and financial ratio benchmarking of Global Cord Blood (CO) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q4 2022
Competitors Tracked
-
Publicly traded peers
Peer Group Market Share
100.00 %
vs 100.00 % a year ago
Revenue Growth Y/Y
10.80 %
Q4 2022
Net Margin
40.98 %
Q4 2022

Key Findings: Global Cord Blood vs Its Competitors

  • TTM: Trailing 12-month revenue of 194M vs -M combined for tracked competitors (100.0% combined share).
  • Trending: Latest-quarter revenue run-rate is accelerating (+305.0% annualized vs trailing 12 months).
  • Peer revenue share: Global Cord Blood accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.

Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).

CO Sales vs. its Competitors, Q4 2022

Global Cord Blood generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.

API endpoints for this dataset
https://api.csimarket.com/api/v1/companies/CO/competitors
https://api.csimarket.com/api/v1/companies/CO/relationships
https://api.csimarket.com/api/v1/companies/CO/similar
Programmatic access for models, analytics, and integration workflows.

For context: the Healthcare Facilities industry grew revenue 14.8% year over year, combined, vs 10.8% for Global Cord Blood. Global Cord Blood's share of combined industry revenue moved from 0.17% to 0.17%, a loss of 0.01 percentage points.

Global Cord Blood's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity Profitable Expanding Above Industry Growth Distressed
Global Cord Blood Corp Yes Yes Yes No
Similar Growth & Profitability (8) 87.50 % (7 of 8) 87.50 % (7 of 8) 75.00 % (6 of 8) 12.50 % (1 of 8)

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

Market Share of the Peer Group, Q4 2022

100%market share
  • Global Cord Blood100.0%
  • Competitors combined0.0%

Share of combined quarterly revenue of Global Cord Blood and its 0 tracked competitors.

See Global Cord Blood's full market share breakdown »

CO Stock Performance relative to its Competitors

CO Competitors (weighted) Percent change over the selected range

CO Stock Performance relative to Similar Growth & Profitability Competitors

CO Similar Growth & Profitability Competitors (equal-weighted, 8) Percent change over the selected range
Get the full CSIMarket dataset: Subscribe API License